OGN Stock: Insider Activity, Filings & Research
Drillr aggregates AI research, SEC filings, earnings signals and alt-data for OGN. 3 published articles.
Insider Activity
During the 90-day trailing window, OGN recorded one open-market purchase and one open-market sale with net insider buying of $0. SVP and Corporate Controller Lynette Holzbaur executed offsetting transactions on 2026-05-07, purchasing and selling $353.1K in equal amounts, resulting in a neutral insider sentiment score of 50/100 with no cluster buying activity. The stock has appreciated 93.9% over three months, while institutional investors have been distributing holdings according to 13F filings. This marks the first insider buy activity in two quarters.
Updated Jun 4, 2026 · based on SEC Form 4 filings · not investment advice
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 7, 2026 | Holzbaur Lynetteofficer: SVP and Corporate Controller | Sell | 26,448 | $13.35 |
| May 7, 2026 | Holzbaur Lynetteofficer: SVP and Corporate Controller | Buy | 26,448 | $13.35 |
| Apr 2, 2026 | Drinane Juliana Papaofficer: Interim Head of Mfg & Supply | Option | 10,073 | — |
| Apr 2, 2026 | Falcione Aaronofficer: Chief Human Resources Officer | Option | 6,732 | — |
| Apr 2, 2026 | Karp Danielofficer: Executive VP, Corp. Dev. | Option | 6,715 | — |
| Apr 2, 2026 | Karp Danielofficer: Executive VP, Corp. Dev. | Tax | 2,105 | $5.70 |
| Apr 2, 2026 | Drinane Juliana Papaofficer: Interim Head of Mfg & Supply | Grant | 125,208 | — |
| Apr 2, 2026 | Holzbaur Lynetteofficer: SVP and Corporate Controller | Tax | 1,914 | $5.70 |
| Apr 2, 2026 | Morrissey Joseph T. Jr.officer: Interim CEO | Option | 16,789 | — |
| Apr 2, 2026 | Weaver Kirkeofficer: Gen. Counsel & Corp. Secy. | Option | 12,312 | — |
| Apr 2, 2026 | Falcione Aaronofficer: Chief Human Resources Officer | Grant | 166,944 | — |
| Apr 2, 2026 | Arjona Ferreira Juan Camiloofficer: Head of R&D & CMO | Option | 13,431 | — |
| Apr 2, 2026 | Drinane Juliana Papaofficer: Interim Head of Mfg & Supply | Option | 6,378 | — |
| Apr 2, 2026 | Holzbaur Lynetteofficer: SVP and Corporate Controller | Tax | 1,212 | $5.70 |
| Apr 2, 2026 | WALSH MATTHEW Mofficer: Chief Financial Officer | Grant | 83,472 | — |
Source: OGN SEC Form 4 filings, latest May 7, 2026. For informational purposes only — not investment advice.
Research
OGN: Sun Pharma Locks $12B Buyout, Below Rumored Range
Sun Pharma confirmed a $12 billion Organon acquisition on April 27, $1B below the rumored price but still likely to pressure SUNP shares 4-7% on dilution concerns while OGN rallies 9-15% on the acquisition premium over the next 1-3 trading days.
SUNPOGN: Sun Pharma Locks $12B Deal, 90% Below Bid Range
Sun Pharma and Organon announced a definitive $12 billion acquisition agreement on April 27, settling what Wall Street had priced as a 90% no-deal scenario. Organon faces 22-28% upside on the confirmed premium while Sun Pharma confronts 5-7% downside on overpayment concerns, with the thesis breaking if either stock moves >10% on unrelated news before deal close.
SUNPOGN: Sun Pharma's $12B Buyout Lands $1B Below Rumored Price
Sun Pharma confirmed a $12 billion Organon acquisition on April 27, $1 billion below the rumored price. The market is treating this as neutral-to-negative for SUNP, but the deal delivers immediate scale in women's health and biosimilars at 1.2x revenue, with $450M+ in synergies driving 20%+ upside over 12-18 months as earnings accretion becomes visible.
SUNP
Track OGN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free